Artiva Biotherapeutics, Inc. · NASDAQ:ARTV
Artiva Biotherapeutics — Corporate Update (November 2025)
30 slides from Artiva Biotherapeutics's corporate update, Nov 12, 2025
Slide 1: AlloNK Initial Safety and Translational Data in Autoimmune Diseases
Artiva Biotherapeutics AlloNK Initial Safety and Translational Data in Autoimmune Diseases November 12, 2025 Artiva Biotherapeutics
Slide 2: Disclaimers and Forward-looking Statements
Disclaimers and Forward-looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking
Slide 3: Deep B-Cell Depletion Approaches Represent Next Wave in Autoimmune Diseases
“Deep B-Cell Depletion” Approaches Represent Next Wave in Autoimmune Diseases Deep B-Cell Depletion Targeted Therapies (RTX, TNFi, JAKi, etc.) Rx in 1990s AlloNK’s Lead Indication: Refractory RA Artiva Biotherapeutics 3
Slide 4: Agenda
Agenda AlloNK Mechanism of Action and Fred Aslan, M.D. Treatment Regimen President & Chief Executive Officer Safety Data from 32 Patients with Autoimmune Subhashis Banerjee, M.D. Diseases Treated with AlloNK + CD20 mAb Chief Medical Officer Initial Translational Data: AlloNK + mAb in Heather Raymon,
Slide 5: AlloNK Mechanism of Action and Treatment Regimen
AlloNK Mechanism of Action and Treatment Regimen Artiva Biotherapeutics 5
Slide 6: AlloNK's Differentiated Mechanism of Action and Scalability
AlloNK’s Differentiated Mechanism of Action and Scalability NK cell + mAb: ADCC via CD16 receptor “Manufacturing-first” Scalable manufacturing process producing CD16 (Fc receptor) is a strong NK cell activating receptor over 4000 vials from 1 cord blood unit bypassing inhibitory signaling NK Selecti
Slide 7: Focusing on Autoimmunity from a Position of Strength in B-NHL
Focusing on Autoimmunity from a Position of Strength in B-NHL Trials in B-NHL Median CAR-T Aggressive Comparator n prior lines naïve B-NHL Complete Response Rate (%) Median DoR (mo) Artiva AlloNK + Rituximab1 14 3 100% 93% 64 Not reached/>19.4m median f/u Breyanzi (auto-CAR-T)2 257 3 100% 100% 53 23
Slide 8: Role of Conditioning with Cy / Flu in Treatment with AlloNK
Role of Conditioning with Cy / Flu in Treatment with AlloNK Cy Dose used: 0.9-1g/m2 Euro-Lupus protocol (3g total); minimal infection risk or impact on fertility1,2,3 6 monthly doses (540mg/m 2 total) found to be well tolerated with only minor Flu Dose used: 90mg/m2 infections noted4 NK cell persist
Slide 9: Treatment Regimen Designed for Outpatient Administration
Treatment Regimen Designed for Outpatient Administration Day 1 Day 2 Day 3 Day 6 Day 13 Day 20 Outpatient Administration Potential for adoption in a community setting AlloNK Regimen AlloNK Dose: 1B or 4B Cy / Flu conditioning Monoclonal Antibody Artiva Biotherapeutics 9
Slide 10: Illustrative AlloNK Treatment Paradigm
Illustrative AlloNK Treatment Paradigm BASELINE 24 Weeks Durability TBD Regulatory endpoint Responder AlloNK Additional cycle for “EXTENSION of effect” First cycle AlloNK Non-Responder First 30 days Target: off immunomodulatory drugs, weaned off steroids “First Cycle”-only responder “Extension Cycle
Slide 11: Safety Data from Patients with Autoimmune Diseases Treated with AlloNK + CD20 mAb
Safety Data from 32 Patients with Autoimmune Diseases Treated with AlloNK + CD20 mAb Artiva Biotherapeutics 11
Slide 12: AlloNK Clinical Development: Ongoing Trials in Autoimmune Diseases
AlloNK Clinical Development: Ongoing Trials in Autoimmune Diseases Phase 2 Basket Trial: RA, SjD, IIMs, SSc Patients receiving treatment • AlloNK + RTX regimen at rheumatology sites with • 1B or 4B cells per AlloNK dose no specialized oncology oversight • No required hospitalization or stagger IIT:
Slide 13: Initial Safety Data for AlloNK + mAb Shows Favorable Tolerability Profile for Community Setting
Initial Safety Data for AlloNK + mAb Shows Favorable Tolerability Profile for Community Setting Grade 3+ TEAEs (none related to AlloNK) • As of data cutoff of October 1, 32 patients treated with AlloNK + mAb Reported Term for the across autoimmune trials dosed at either 1B cells or 4B cells per dose
Slide 14: AlloNK's Tolerability Profile Compares Favorably to Autologous CAR-T and T-Cell Engagers
AlloNK’s Tolerability Profile Observed to Date Compares Favorably to Autologous CAR-T and BCMA Targeted T-Cell Engagers Deep B-cell Depletion Datasets Auto CAR-T T-Cell Engager AlloNK Schett / CASTLE1 teclistamab2 No. of Patients 32 24 10 CRS (any Gr / Gr 3+) -/- 75% / - 80% / - ICANS (any Gr / Gr 3
Slide 15: Hospitalization Rates Consistent with mAb Alone, Showing Ability to Manage Outpatients
δ Experience from first 32 Patients Treated with AlloNK + mAb: Hospitalization Rates Consistent with mAb Alone Showing Ability to Manage Patients as Outpatient (Each row represents one patient) IIT • No hospitalizations for AE related to AlloNK treatment • Only 1 patient hospitalized for an Company-
Slide 16: Similarities and Differences to Managing Patients Treated with Cy / Flu + AlloNK + mAb vs. RTX Alone
Similarities and Differences to Managing Patients Treated with Cy / Flu + AlloNK + mAb vs. RTX Alone AlloNK Treatment Regimen: RTX – Approved 1997 Cy / Flu + AlloNK + mAb Used in Over 200,000 Patients1 Premedication to Minimize Infusion Related Premedication to Minimize Infusion Reactions Related Re
Slide 17: Initial Translational Data: AlloNK + mAb in Autoimmune Diseases
Initial Translational Data: AlloNK + mAb in Autoimmune Diseases Artiva Biotherapeutics 17
Slide 18: AlloNK + Anti-CD20 mAbs Shows Consistent Complete B-Cell Depletion in Autoimmune Diseases
AlloNK + Anti-CD20 mAbs Shows Consistent Complete B-Cell Depletion in Autoimmune Diseases Uniform and consistent B-cell depletion observed by Day 13 in all 23 patients with autoimmune diseases treated with Cy / Flu + AlloNK + anti-CD20 mAb (RTX or OBI) with samples analyzed as of data cutoff LD 6 mo
Slide 19: RTX Incomplete Depletion Becomes Evident with High Sensitivity Assay
RTX Incomplete Depletion Becomes Evident with High Sensitivity Assay B-cell Depleting Studies Typically Only Show Results using RTX Shows Incomplete Depletion using Lower Sensitivity TBNK Assays (~10 cells/µl) High Sensitivity Assay Blinatumomab (CD19 TCE) B-cell depletion in 6 patients with RA1 Med
Slide 20: Complete and Deep B-Cell Depletion Seen by High Sensitivity Assay for AlloNK + mAb
Complete and Deep B-Cell Depletion Seen As Measured by High Sensitivity Assay for AlloNK + mAb Represents B-cell depletion in one patient with autoimmune disease who received Cy / Flu + AlloNK as their first cycle and the full treatment regimen as their second cycle • Cy / Flu + AlloNK (no mAb): B-
Slide 21: First Patients Treated with AlloNK + RTX All Show Complete B-Cell Depletion
First 17 Patients Treated with AlloNK + RTX All Show Complete B-Cell Depletion Using High Sensitivity Assay Percent of Patients with Quantifiable B-cells at Various Follow Up Time Points • RTX alone has shown incomplete depletion utilizing the high sensitivity assay in RA and SLE patients, with B-ce
Slide 22: Increase in Naïve / Transitional B-Cells Following B-Cell Depletion with AlloNK + mAb
Increase in Naïve / Transitional B-Cells Following B-Cell Depletion with AlloNK + mAb Consistent with CD19 auto-CAR T Experience Percent of Naïve B-cells in Patients Treated with AlloNK + RTX Consistent with Auto-CAR T Experience Mackensen 20221 AlloNK + RTX 100 • B-cell subsets in patients with B-c
Slide 23: Unmet Need and Opportunity in Refractory RA
Unmet Need and Opportunity in Refractory RA Artiva Biotherapeutics 23
Slide 24: Playing to our Strengths: Focusing on Indications with Largest Unmet Need in the Community Setting
Playing to our Strengths: Focusing on Indications with Largest Unmet Need in the Community Setting Prevalence, US and Europe* (Thousands) 3,800 840 425 215 145 RA SjD SLE (incl. LN) SSc IIMs Community Access Tertiary Care Access Importance of Community Setting Access (Highest to Lowest) • Leading wi
Slide 25: Framing Unmet Need in Refractory RA Through Lens of ACR50
Framing Unmet Need in Refractory RA Through Lens of ACR50 100% Permanent joint damage, pain conditions like fibromyalgia % of RA patients The RA “Ceiling Effect” achieving 50% ACR50 Response Immunomodulatory control 0% Artiva Biotherapeutics 25
Slide 26: Framing Unmet Need in Refractory RA Through Lens of ACR50
Framing Unmet Need in Refractory RA Through Lens of ACR50 100% Permanent joint damage, pain conditions like fibromyalgia % of RA patients achieving ACR50 The RA “Ceiling Effect” AlloNK’s 50% Response 45 opportunity: 39 36 ACR50 in ≥50% of 27 refractory RA 20 10-20% patients 0% Upadacitinib, Adalimum
Slide 27: Significant Market Opportunity and Limited Late-Stage Therapies for RA Create Opportunity for AlloNK + RTX
Significant Market Opportunity and Limited Therapies for RA in Late-Stage Development Create Opportunity for AlloNK + RTX in Refractory RA >$25bn in Peak Sales in RA for the Top 5 Approved Products Alone 1… …And Limited Therapies Targeting Peak Sales in RA ($ bn) Novel Mechanisms in Late-Stage Devel
Slide 28: Opportunity to Break Away: Potential to be First Deep B-Cell Depleting Agent in a Pivotal Trial in Refractory RA
Opportunity to “Break Away”: Potential to be First Deep B-Cell Depleting Agent in a Pivotal Trial in Refractory RA Lead Indication in Potential to be First Execution and Financial Data-Driven Approach Refractory RA with B-Cell Depleting Agent Strength to Deliver in other Indications Significant Unme
Slide 29: Thank you
Thank you https://www.artivabio.com | NASDAQ: ARTV
Slide 30: Q&A
Q&A Fred Aslan, M.D. Heather Raymon, Ph.D. President & Chief Executive SVP, Research & Early Officer Development
Artiva Biotherapeutics — Corporate Update (November 2025) on 6ix